79 related articles for article (PubMed ID: 7651449)
1. Antiparkinsonian therapies and brain mitochondrial complex I activity.
Przedborski S; Jackson-Lewis V; Fahn S
Mov Disord; 1995 May; 10(3):312-7. PubMed ID: 7651449
[TBL] [Abstract][Full Text] [Related]
2. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity.
Przedborski S; Jackson-Lewis V; Muthane U; Jiang H; Ferreira M; Naini AB; Fahn S
Ann Neurol; 1993 Nov; 34(5):715-23. PubMed ID: 8239566
[TBL] [Abstract][Full Text] [Related]
3. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
[TBL] [Abstract][Full Text] [Related]
4. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders.
Ben-Shachar D; Zuk R; Gazawi H; Ljubuncic P
Biochem Pharmacol; 2004 May; 67(10):1965-74. PubMed ID: 15130772
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain.
Prince JA; Yassin MS; Oreland L
J Pharmacol Exp Ther; 1997 Jan; 280(1):261-7. PubMed ID: 8996205
[TBL] [Abstract][Full Text] [Related]
6. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line.
Pardo B; Mena MA; Fahn S; García de Yébenes J
Mov Disord; 1993 Jul; 8(3):278-84. PubMed ID: 8341291
[TBL] [Abstract][Full Text] [Related]
7. [Effect of a new antiparkinsonian drug himantane on monoamine oxidase activity].
Val'dman EA; Voronina TA; Aksenova LN; Buneeva OA; Medvedev AE
Eksp Klin Farmakol; 2003; 66(5):3-5. PubMed ID: 14650204
[TBL] [Abstract][Full Text] [Related]
8. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Saravanan KS; Sindhu KM; Senthilkumar KS; Mohanakumar KP
Neurochem Int; 2006 Jul; 49(1):28-40. PubMed ID: 16490285
[TBL] [Abstract][Full Text] [Related]
9. Neuroleptic medications inhibit complex I of the electron transport chain.
Burkhardt C; Kelly JP; Lim YH; Filley CM; Parker WD
Ann Neurol; 1993 May; 33(5):512-7. PubMed ID: 8098932
[TBL] [Abstract][Full Text] [Related]
10. Modulation of brain mitochondrial function by deprenyl.
Czerniczyniec A; Bustamante J; Lores-Arnaiz S
Neurochem Int; 2006 Feb; 48(3):235-41. PubMed ID: 16289465
[TBL] [Abstract][Full Text] [Related]
11. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
12. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
Carta M; Carlsson T; Kirik D; Björklund A
Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
[TBL] [Abstract][Full Text] [Related]
13. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease.
Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM
Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221
[TBL] [Abstract][Full Text] [Related]
14. l-DOPA administration enhances 6-hydroxydopamine generation.
Maharaj H; Sukhdev Maharaj D; Scheepers M; Mokokong R; Daya S
Brain Res; 2005 Nov; 1063(2):180-6. PubMed ID: 16257392
[TBL] [Abstract][Full Text] [Related]
15. Improvement of mouse brain mitochondrial function after deprenyl treatment.
Czerniczyniec A; Bustamante J; Lores-Arnaiz S
Neuroscience; 2007 Jan; 144(2):685-93. PubMed ID: 17084986
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
Willis GL
Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
[TBL] [Abstract][Full Text] [Related]
17. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
[TBL] [Abstract][Full Text] [Related]
18. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
Biggs CS; Starr MS
Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
[TBL] [Abstract][Full Text] [Related]
19. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
20. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
